Stifel Nicolaus Initiates Proteon Therapeutics At Buy, Shares Rise

by Monica Gerson, Benzinga Staff Writer
November 17, 2014 8:43 AM | 12 seconds read |
Analysts at Stifel Nicolaus initiated coverage on shares of Proteon Therapeutics PRTO with a Buy rating. The target price for Proteon Therapeutics is set to $17. Proteon Therapeutics' shares gained 5.16% to $10.60 in pre-market trading.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: InitiationAnalyst RatingsStifel Nicolaus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!